For example, patients carrying the GLP1R rs6923761 variant may experience different semaglutide efficacy compared to those without this variant, while GIPR rs1800437 status influences GIP pathway responsiveness
The most common side effects include mild nausea, diarrhea, or abdominal discomfort, particularly in the first few weeks of treatment
Most people start noticing subtle improvements in energy levels and overall well-being within 1-2 weeks of starting treatment
[4] The common side effects experienced by users and identified by clinicians are reflected by findings from the SURPASS/SURMOUNT clinical trial programmes
Doing so could lead to an increased risk of gastrointestinal side effects without proven benefits
Allergic Reactions: Urticaria, rash, or anaphylaxis